iPS cell transplantation for traumatic spinal cord injury.
iPS cell transplantation for traumatic spinal cord injury.
复制标题
DOI：
10.2174/1574888x10666150723150059
复制
发表时间：
2016
影响因子：
2.7
通讯作者：
Lepore AC
中科院分区：
文献类型：
--
作者：
Goulão M;Lepore AC
在创伤性脊髓损伤(SCI)模型中，已发表了大量关于移植来自发育中和成年中枢神经系统以及来自多潜能胚胎干细胞的神经干细胞和祖细胞类型的工作。然而，这些基于细胞的方法中的许多方法为临床翻译带来了实际问题，如伦理细胞来源、潜在的大量均质制备细胞的产生和免疫排斥。随着诱导多能干细胞(IPS)技术的出现，这些问题中的许多可能被克服。到目前为止，许多研究已经证明了iPS细胞在各种脊髓损伤模型中的整合、分化为成熟的中枢神经系统谱系、迁移和长期安全性，以及在某些情况下的治疗效果。考虑到干细胞生物学的这一进展的临床潜力，我们简要回顾了迄今为止发表的涉及脊髓损伤动物模型中iPS细胞移植的研究。
A large body of work has been published on transplantation of a wide range of neural stem and progenitor cell types derived from the developing and adult CNS, as well as from pluripotent embryonic stem cells, in models of traumatic spinal cord injury (SCI). However, many of these cell-based approaches present practical issues for clinical translation such as ethical cell derivation, generation of potentially large numbers of homogenously prepared cells, and immune rejection. With the advent of induced Pluripotent Stem (iPS) cell technology, many of these issues may potentially be overcome. To date, a number of studies have demonstrated integration, differentiation into mature CNS lineages, migration and long-term safety of iPS cell transplants in a variety of SCI models, as well as therapeutic benefits in some cases. Given the clinical potential of this advance in stem cell biology, we present a concise review of studies published to date involving iPS cell transplantation in animal models of SCI.